Print
Email
Print Edition StoriesWednesday, February 27, 2008
CombinatoRx collects patent on drug cocktail
Biotechnology firm CombinatoRx Inc. reports it has garnered a U.S. patent on drug combinations for the treatment of inflammatory disorders.
The patent includes claims that cover CRx-191, the Cambridge biotech's topical dermatology drug candidate, as well as other potential treatments. The patent is due to expire in 2022.
CombinatoRx (Nasdaq: CRXX) is developing CRx-191, which is a combination of tricyclic antidepressants and glucocorticosteriods, to treat inflammation of the skin. The drug is in Phase 2 clinical trials for plaque psoriasis, and the firm has completed a safety study of the treatment for skin atrophy.
CombinatoRx, which combines approved drug molecules for new uses, reported a 2006 net loss of $34.3 million on revenue of $13.3 million. The biotech employs 144 workers.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
